{'fraction_non_alphanumeric': 0.025023169601482854, 'fraction_numerical': 0.011121408711770158, 'mean_word_length': 5.75, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Chemotherapy for resistant and relapsing multiple myeloma

This report summarizes a broad experience in the treatment of patients with multiple myeloma resistant to standard chemotherapy. The VAD regimen has induced remissions in about 50% of relapsing patients but in only about 25% of previously unresponsive patients. In patients resistant to VAD, high‐dose therapies with intravenous melphalan, a CBV combination (cyclophosphamide‐BCNU‐VP‐16) or an EDAP regimen (VP‐16 ‐platinum) produced responses in about 40% of patients. However, these treatments usually required autologous bone marrow or blood stem cell support and the median duration of control was only 6 months. With an even more intensive program using high‐dose melphalan and total body irradiation supported by autologous bone marrow, all patients who survived the early treatment period responded for a median duration of about 1 year. Results indicated a dose‐response effect of chemoradiotherapy on VAD‐resistant myeloma with the potential that such intensive regimens will prolong disease‐free survival time.